Talphera, Inc. reported its financial results for the third quarter of 2025, revealing a net loss of $4.4 million, or $0.11 per share, compared to a net loss of $3.4 million, or $0.13 per share, for the same period in 2024. For the nine months ended September 30, 2025, the company recorded a net loss of $10.5 million, slightly down from $11.1 million in the prior year. Revenue for the quarter was nominal at $1, while total revenue for the nine-month period reached $28, marking a significant increase from zero in the previous year. The company’s accumulated deficit as of September 30, 2025, stood at $467.7 million.
In terms of operational changes, Talphera's total assets increased to $30.7 million from $18.2 million at the end of 2024, primarily due to a rise in cash and short-term investments, which totaled $21.3 million as of September 30, 2025, compared to $8.9 million at the end of the previous year. The increase in cash was bolstered by recent private placements, including a $17 million capital raise in September 2025, where the company issued over 25 million shares at $0.55 each. The company also reported a significant increase in its outstanding shares, rising to 45.6 million from 17 million at the end of 2024.
Talphera continues to focus on its lead product candidate, Niyad™, a regional anticoagulant for dialysis, which has received Breakthrough Device Designation from the FDA. The company is currently conducting a registrational study, NEPHRO CRRT, which has been streamlined to include 70 patients, down from the originally planned 166. This adjustment aims to expedite the clinical trial process and facilitate earlier regulatory submission. The company is also exploring additional product candidates, including LTX-608, which is intended for various indications, including acute respiratory distress syndrome.
Despite these developments, Talphera faces ongoing challenges, including the need for additional capital to fund its operations and product development. The company has indicated that it may require further financing within the next twelve months to sustain its operations, which could involve public or private equity offerings or other strategic partnerships. The management has expressed concerns regarding the potential impact of macroeconomic factors, such as inflation and supply chain disruptions, on its business operations and financial condition. The company remains committed to advancing its product pipeline while navigating these financial and operational hurdles.
About TALPHERA, INC.
Talphera, Inc. is a specialty pharmaceutical company developing innovative therapies for use in medically supervised settings. Its portfolio includes nafamostat-based product candidates for anticoagulation, antiviral, and inflammatory indications, targeting hospital and critical care markets. The company focuses on obtaining regulatory approvals, advancing clinical trials, and commercializing therapies that address unmet medical needs, leveraging proprietary formulations, patents, and strategic partnerships.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.